108 related articles for article (PubMed ID: 3476200)
21. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
[TBL] [Abstract][Full Text] [Related]
23. Tiazofurin action in leukemia: evidence for down-regulation of oncogenes and synergism with retinoic acid.
Weber G; Yamaji Y; Nagai M; Natsumeda Y; Jayaram HN; Zhen WN; Paulik E
Adv Enzyme Regul; 1990; 30():35-45. PubMed ID: 2206022
[TBL] [Abstract][Full Text] [Related]
24. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
25. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
27. Relapse of acute myeloblastic leukemia lasting for four years. Production by leukemic cells of colony-stimulating activity and non-production of leukemia-associated inhibitor.
Giannoulis N; Reizenstein P; Ost A
Acta Med Scand; 1981; 210(1-2):139-43. PubMed ID: 6945794
[TBL] [Abstract][Full Text] [Related]
28. Unique bioactivation of tiazofurin--studies with resistant cells.
Kuttan R
Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of resistance to tiazofurin in hepatoma 3924A.
Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
[TBL] [Abstract][Full Text] [Related]
30. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
[No Abstract] [Full Text] [Related]
32. Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease.
Notario A; Rolandi ML; Mazzucchelli I
Haematologica; 1996; 81(3):261-4. PubMed ID: 8767533
[TBL] [Abstract][Full Text] [Related]
33. Tiazofurin decreases Ras-GTP complex in K562 cells.
Hata Y; Natsumeda Y; Weber G
Oncol Res; 1993; 5(4-5):161-4. PubMed ID: 8305741
[TBL] [Abstract][Full Text] [Related]
34. The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.
Arnold ST; Jayaram HN; Harper GR; Litterst CL; Malspeis L; DeSouza JJ; Staubus AE; Ahluwalia GS; Wilson YA; Cooney DA
Drug Metab Dispos; 1984; 12(2):165-73. PubMed ID: 6144481
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.
Raghavan D; Bishop J; Sampson D; Grygiel J; Woods R; Coates A; Fox R
Cancer Chemother Pharmacol; 1986; 16(2):160-4. PubMed ID: 3948303
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
Vogler WR; Trulock PD
Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
[TBL] [Abstract][Full Text] [Related]
38. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
Melink TJ; Sarosy G; Hanauske AR; Phillips JL; Bayne JH; Grever MR; Jayaram HN; Von Hoff DD
Sel Cancer Ther; 1990; 6(1):51-61. PubMed ID: 2343202
[TBL] [Abstract][Full Text] [Related]
40. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
